Allegion’s SVP Kemp sells $634,785 in shares
NEW YORK - Baird Medical (TASE:PMCN) Investment Holdings Ltd. (NASDAQ: BDMD), a $247.59 million market cap company known for its minimally invasive Microwave Ablation (MWA) technology, announced its expansion into San Francisco, a move seen as a significant step in its growth strategy within the United States. The company maintains impressive gross profit margins of 88.41%, according to InvestingPro data. The company's MWA system, which received FDA 510(k) clearance in November 2023, has since been adopted by numerous physicians across the country, including Dr. Terrence K. Trapp in San Francisco and Dr. Emad Kandil at Tulane University, who has completed over 100 MWA procedures.
The technology, which is used to treat conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer, has been integrated into various practices due to its positive treatment outcomes and significant patient recovery rates. Trading at a P/E ratio of 15.71, the stock has shown resilience with strong recent performance, despite experiencing a 37.32% decline over the past six months. The company's recent participation in the J.P. Morgan Health Conference in San Francisco underscored its early success and commitment to medical innovation.
Baird Medical's approach includes collaborating with medical specialists and providing comprehensive training and clinical support to expand physician education and awareness of MWA technology in the U.S. By entering the San Francisco market, Baird Medical aims to improve access to minimally invasive treatment options, which could benefit both physicians and patients.
The company's forward-looking statements, as defined under the United States Private Securities Litigation Reform Act of 1995, indicate future aspirations and potential financial or operational performance. With a beta of -0.68, the stock typically moves counter to market trends. InvestingPro subscribers can access 8 additional key insights and detailed financial metrics to better evaluate BDMD's investment potential. However, these statements are subject to various risks, uncertainties, and assumptions that could affect the company's actual results. Factors that could influence outcomes include the company's ability to achieve its expansion goals, changes in economic or market conditions, regulatory developments, and the commercial success of its products.
This expansion news is based on a press release statement and offers a factual account of Baird Medical's current developments and strategic endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.